{"id":"NCT00091949","sponsor":"Yale University","briefTitle":"Insulin Resistance Intervention After Stroke Trial","officialTitle":"Insulin Resistance Intervention After Stroke (IRIS) Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-02","primaryCompletion":"2015-11","completion":"2015-11","firstPosted":"2004-09-22","resultsPosted":"2016-10-28","lastUpdate":"2020-04-27"},"enrollment":3876,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Stroke","Myocardial Infarction","Diabetes"],"interventions":[{"type":"DRUG","name":"pioglitazone","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Pioglitazone","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if pioglitazone is effective in preventing future strokes or heart attacks among non-diabetic persons who have had a recent ischemic stroke.","primaryOutcome":{"measure":"Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction","timeFrame":"Up to 5 years","effectByArm":[{"arm":"Pioglitazone","deltaMin":175,"sd":null},{"arm":"Placebo","deltaMin":228,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":".0067"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":183,"countries":["United States","Australia","Canada","Germany","Israel","Italy","Puerto Rico","United Kingdom"]},"refs":{"pmids":["25458644","19365056","21824978","39921499","30734043","29934374","29084736","28975241","28959471","28939682","28246237","27935736","27465265","26886418","21998067"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":950,"n":1939},"commonTop":["Edema","Shortness of breath","Excessive weight gain","Bone fracture"]}}